FREE Case Review (866) 588-0600

Xeljanz Blood Clots Lawsuit | Get the Right Lawyer

The rheumatoid arthritis drug Xeljanz (generic: tofacitinib) has recently been linked to an increased risk for severe, potentially fatal blood clots including pulmonary embolism (blood clot in the lungs) and deep vein thrombosis (clot in the legs, arm, or pelvis).
Awards & recognition

Free Xeljanz Blood Clots Lawsuit Review
If you or a loved one developed a deep vein thrombosis (DVT), pulmonary embolism, or other type of blood clot after taking Xeljanz, you should contact our personal injury attorneys immediately for a free case review. Our Xeljanz attorneys are actively investigating lawsuits in all 50 states.

Please click the button below for a Free Case Evaluation or contact our law firm toll-free 24 hrs/day by dialing (866) 588-0600 if you had serious heart related problems after taking Xeljanz.

Start My Free Xeljanz Blood Clots Lawsuit Review

Clinical Trials Link Xeljanz to Blood Clots in the Lungs

In a post-marketing study, Xeljanz was found to dramatically increase the risk of a blood clot developing and then traveling to the lungs to cause a pulmonary embolism, especially when taken at a high dose.

The study looked at 4,400 test subjects, all of whom have at least one cardiovascular risk factor, and was designed to compare the efficacy and safety of Xeljanz to a tumor necrosis factor inhibitor drug in people with rheumatoid arthritis.

The trial aimed to find out whether Xeljanz was more or less safe for people who have higher cardiovascular risks, and monitored their heart health and whether they developed malignancies or cancer.

Pfizer intervened in the study on February 19, 2019, to take participants off of the twice-daily dose of 10 milligrams. The decision was made after Pfizer was notified by the Rheumatology Data Safety Monitoring Board that a high number of participants in that dosage level were developing blood clots in their lungs and suffering pulmonary embolisms.

People taking the high dosage of Xeljanz were suffering pulmonary embolisms more than five times as often as people taking the tumor necrosis factor inhibitor drug. They were also suffering pulmonary embolisms three times as often as other Xeljanz participants in that trial and others like it.

Pfizer’s announcement was likely spurred by the FDA’s announcement about Xeljanz in February 2019, which warned the public of the potential for a blood clot reaching the lungs after taking the drug.

Related Articles:

See all related dangerous drug lawsuits our lawyers have covered.

What is a Blood Clot?

Blood clots are gel-like collections of blood that form in a person’s veins or arteries when blood changes from liquid to partially solid. Clotting is a normal function that stops the body from bleeding too much when you get hurt. However, blood clots that form in some places and don’t dissolve on their own can be dangerous to your health.

When a blood clot forms where it should not have developed, it is called a thrombus. The clot may stay in one spot (called thrombosis) or move through the body (called embolism or thromboembolism). The clots that move are especially dangerous. Blood clots can form in arteries (arterial clots) or veins (venous clots).

Blood Clot Symptoms

Deep Vein Thrombosis Symptoms

  • Swelling
  • Pain
  • Tenderness
  • Redness of the skin

Pulmonary Embolism Symptoms

  • Difficulty breathing
  • Faster than normal or irregular heartbeat
  • Chest pain or discomfort, which usually worsens with a deep breath or coughing
  • Coughing up blood
  • Very low blood pressure, lightheadedness, or fainting

Treatment

Treatment for blood clots depends on where the clot is in the body, and the severity of the condition. Blood-thinning medications are commonly used to prevent blood clots from forming or getting bigger. Thrombolytic medications can break up existing clots.

Catheter-directed treatments, such as percutaneous transcatheter treatment, are done by inserting a catheter into a blood vessel in the groin. The tube is moved to the site of the clot and used to break up the clot or deliver clot-dissolving thrombolytic drugs directly.

Surgical thrombectomy, in which the clot is surgically removed from the vein or artery, is often used in arms or legs, but can be used elsewhere in the body.

For patients who are at high risk of developing a deep vein thrombosis, preventive measures should be considered. In addition to or instead of blood thinners, intermittent pneumatic compression (IPC) devices can be very effective. A cuff is placed around the leg, where it periodically fills with air and squeezes, helping move blood toward the heart.

Get a Free Xeljanz Blood Clots Lawsuit Evaluation With Our Lawyers

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial attorneys that focus on the representation of plaintiffs in Xeljanz lawsuits. We are handling individual litigation nationwide and currently accepting new blood clot injury and death cases in all 50 states.

Free Xeljanz Blood Clots Lawsuit Evaluation: Again, if you developed a blood clot (pulmonary embolism, deep vein thrombosis, etc.) after taking Xeljanz to treat rheumatoid arthritis, you should contact our attorneys immediately. Xeljanz patients may be entitled to compensation for medical expenses by filing a Xeljanz blood clots lawsuit and our Xeljanz Attorneys can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.